Accentia Biopharmaceuticals’s Development Partner BioDelivery Sciences International Requests Meeting With FDA To Gain Clarification Of Non-Approvable Letter For Emezine(R)

TAMPA, Fla.--(BUSINESS WIRE)--March 1, 2006--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) has received notification that its third-party developer for Emezine(R) (prochlorperazine maleate), BioDelivery Sciences International Inc., was issued a non-approvable letter from the U.S. Food and Drug Administration (FDA) for BioDelivery's New Drug Application (NDA) submitted under Section 505(b)(2) in May 2005. The letter, delivered February 28, 2006, recommended that BioDelivery provide additional information to the FDA. In response, BioDelivery requested a meeting with the FDA.